Joint Venture Between CHA Biotech and Advanced Cell Technology to be called “Stem Cell & Regenerative Medicine International”

WORCESTER, Mass.--(BUSINESS WIRE)--The joint venture between Advanced Cell Technology, Inc. (OTC:ACTC) and leading Korean-based biotechnology company CHA Biotech Co, Ltd. (CHA), announced today that the company would be named “Stem Cell & Regenerative Medicine International.”

MORE ON THIS TOPIC